uniQure reported AMT-130 data as uniQure stock faces FDA review

Published on 10/18/2026 at 13:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS set a USD 48.00 target for uniQure stock on October 14, 2026. Q2 2026 revenue was USD 5.84 million versus USD 5.26 million.

Regulatory path and quarterly figures

uniQure reported 44.00 percent slowing after 48 months versus 75.00 percent after 36 months on September 29, 2026.
Second-quarter 2026 revenue reached USD 5.84 million against USD 5.26 million in the prior-year quarter.
MarketBeat lists November 9, 2026, as the estimated date for uniQure's third-quarter results.

QURE, NL0010696654, Illustration mit AI erstellt.

uniQure N.V. reported that AMT-130 slowed Huntington's disease progression by 44.00 percent after 48 months, compared with 75.00 percent after 36 months. The update dated September 29, 2026, keeps the regulatory review of the gene therapy at the center of the investment case, according to uniQure.

AMT-130 data set the frame

The longer follow-up produced a smaller measured treatment effect than the earlier readout. A report carried by Markets Insider said the 48-month figure was 44.00 percent, versus 75.00 percent at 36 months. That numerical gap is important because the company submitted its Biologics License Application using the 36-month data package.

The chronology is clear. On July 29, 2026, uniQure reported second-quarter revenue of USD 5.84 million, compared with USD 5.26 million in the prior-year quarter, while GAAP net loss widened to USD 81.06 million from USD 37.72 million, according to Markets Insider. On September 2, 2026, the company announced its BLA submission based on 36-month AMT-130 data. On September 29, 2026, it published the 48-month analysis with the 44.00 percent slowing figure.

What comes next for the filings

The next dated item is the expected third-quarter report. MarketBeat lists November 9, 2026, before the market opens as the estimated reporting date. The Nasdaq-listed company therefore enters the next reporting cycle with a clinical result to interpret and a regulatory decision path to advance.

Analyst views remain wide. Markets Insider reported that UBS initiated coverage on October 14, 2026, with a Buy rating and a USD 48.00 target. The same report said Barclays had downgraded the stock to Hold on October 6, 2026, illustrating how strongly valuation depends on the interpretation of AMT-130 evidence.

Market reference for German investors

The last available euro quotation came from Tradegate at EUR 19.96 on October 9, 2026 at 7:59 p.m. CEST. On Nasdaq, the stock was last quoted at USD 21.78 on October 16, 2026 at 4:00 p.m. ET in after-hours data. uniQure has a market capitalization of USD 1.5 billion as of October 16, 2026, while its 52-week range was USD 8.73 to USD 71.50.

The further course of trading is shown by the continuously updated real-time quote of uniQure stock.